Online inquiry

IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5820MR)

This product GTTS-WQ5820MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Psoriasis, Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5820MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1738MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ12238MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ940MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ6353MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ1144MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ268MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ2177MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ15285MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Theraloc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW